Dopa-decarboxylase (DDC), also known as aromatic L-amino acid decarboxylase (AADC), is a crucial enzyme in the biosynthesis of dopamine and other catecholamines. DDC-expressing neurons represent a specialized population of catecholaminergic neurons concentrated in brain regions critical for motor control, reward processing, and autonomic function[@nagatsu2004]. These neurons are the direct cellular targets of Parkinson's disease pathology, and their integrity is routinely assessed using PET imaging in clinical practice.
The enzyme DDC catalyzes the final step in dopamine biosynthesis, converting L-3,4-dihydroxyphenylalanine (L-DOPA)—the immediate product of tyrosine hydroxylation—into the neurotransmitter dopamine. This reaction occurs within the cytosol of dopaminergic neurons, and the enzyme's activity serves as both a marker of dopaminergic neuron survival and a therapeutic target in PD management.
DDC (EC 4.1.1.28) is a pyridoxal phosphate-dependent enzyme that requires vitamin B6 (pyridoxal 5'-phosphate, PLP) as a cofactor. The enzyme catalyzes the decarboxylation of several aromatic L-amino acids:
DDC is localized predominantly in the cytosol of neuronal cell bodies and terminals, with highest concentrations in:
The enzyme's distribution correlates with the density of dopaminergic innervation, making it an excellent marker for dopaminergic neuron integrity.
The largest population of DDC-expressing neurons resides in the SNc. These neurons project to the dorsal striatum (caudate and putamen), forming the nigrostriatal pathway that is primarily affected in PD[@jellinger2015]. SNc DDC neurons:
The VTA contains DDC neurons that project to forebrain regions, forming the mesolimbic and mesocortical pathways. These neurons:
Smaller DDC populations exist in:
DDC activity is significantly reduced in PD, reflecting loss of dopaminergic neurons[@kelley2017]. Studies demonstrate:
Several DDC-targeted PET ligands have been developed for clinical and research use[@choi2011]:
| Ligand | Target | Clinical Use |
|---|---|---|
| 18F-Fluoro-L-DOPA (FDOPA) | DDC activity | PD diagnosis, disease progression |
| 18F-Aminooxy-L-Tyrosine | DDC activity | Research applications |
| 11C-RTI-32 | Dopamine transporter | Complementary to DDC imaging |
These imaging approaches provide information beyond what dopamine transporter (DAT) imaging offers, as they directly measure the functional capacity of surviving neurons.
DDC activity correlates with:
However, DDC activity may be more selectively reduced than other markers in certain conditions, providing unique diagnostic information.
Peripheral DDC inhibitors are standard adjunct therapy in PD[@finberg2019]:
These inhibitors:
Experimental approaches targeting DDC include[@funahashi2023]:
DDC imaging helps differentiate parkinsonian syndromes[@pavese2012]:
| Disorder | DDC Pattern |
|---|---|
| Parkinson's Disease | Moderate, irregular reduction |
| Multiple System Atrophy | Severe, early reduction |
| Progressive Supranuclear Palsy | Severe, early reduction |
| Corticobasal Degeneration | Variable, asymmetric |
Age-related changes in DDC activity include[@育良2011]:
DDC PET imaging is used for:
DDC measurements provide insights into: